Drug intelligence / Profile preview

ORP-101

Development stage: Phase 2
Lead developer: OrphoMed
Modality: Small Molecules
Administration: Oral

Overview

ORP-101 is a new chemical entity and small molecule drug developed by OrphoMed for the treatment of irritable bowel syndrome with diarrhea (IBS-D). It acts as a peripheral partial agonist at the μ-opioid receptor and a full antagonist at the κ-opioid receptor. This dual mechanism is designed to address both dysmotility and pain symptoms in IBS-D without causing central nervous system effects or risks such as sphincter of Oddi spasm or pancreatitis. ORP-101 does not cross the blood-brain barrier, making it likely non-addictive. The drug has completed Phase 2 clinical trials and was granted FDA Fast Track designation in 2018[1][4][5][6].

Other names: buprenorphine dimer

Targets

KOR (Kappa opioid receptor)MOR (Mu opioid receptor)

Beyond the preview

Go deeper on ORP-101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ORP-101.

Explore the full profile